TIGIT and small cell lung carcinoma: A large phase 3 trial (NCT04256421, SKYSCRAPER-02) of the TIGIT inhibitor tiragolumab in combination with atezolizumab-carboplatin-etoposide for ES-SCLC is currently ongoing.29